Trial reportTranslational psychiatry2026
Optimizing tDCS cognitive outcomes in schizophrenia: the role of dopaminergic tone and antipsychotic load.
Trial report in Translational psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Working memory deficits are a central cognitive impairment in schizophrenia and a key therapeutic target. Transcranial direct current stimulation (tDCS) has emerged as a potential cognitive enhancer, yet considerable interindividual variability limits its clinical utility. Pharmacological modulation of dopaminergic signaling, particularly through antipsychotic medications, may influence neuroplasticity and thereby alter responsiveness to tDCS. This study investigated whether antipsychotic dose or pharmacodynamic profile affects tDCS-related working memory improvements in schizophrenia. In a randomized, double-blind, placebo-controlled trial, 120 clinically stable outpatients received active or sham bifrontal tDCS delivered over 10 consecutive weekdays. Working memory performance was assessed using the MATRICS Consensus Cognitive Battery. Antipsychotic regimens were categorized as full D2 antagonists or partial D2 agonists, and all doses were converted to olanzapine equivalents. Results showed a significant negative correlation between antipsychotic dose and tDCS-induced working memory enhancement (r = -0.197, p = 0.031), indicating diminished cognitive gains at higher doses. In contrast, no significant differences in working memory outcomes emerged between patients receiving full antagonists versus partial agonists. These findings suggest that overall dopaminergic blockade, rather than specific receptor-binding profiles, modulates cognitive responsiveness to tDCS. High antipsychotic doses may reduce neuroplastic capacity, thereby limiting the therapeutic potential of neuromodulation. The results highlight the need to consider antipsychotic load in the design and interpretation of cognitive enhancement trials and support the use of pharmacological burden as a stratification variable in precision-psychiatry approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.